Defined Terms Section Sample Clauses
Defined Terms Section. Certificate Section 2.5.2 CGCL Recitals Closing Section 1.2 Closing Date Section 1.2 Code Recitals Combination Cash Election Section 2.2.1 Combination Stock Election Section 2.2.1 Community Reinvestment Act Section 3.7(c) Confidentiality Agreement Section 6.2 Control Transaction Section 11.2 CVBF Preamble CVBF Affiliated Shareholders Recitals CVBF Articles Section 4.2 CVBF Balance Sheet Section 4.9(c) CVBF Bank Recitals CVBF Benefit Plan Section 7.4(a) CVBF Board Section 4.5(a) CVBF Board Approval Section 4.5(b) CVBF Board Recommendation Section 5.3(b) CVBF Bylaws Section 4.2 CVBF Common Stock Certificates Section 2.4(a) CVBF Confidential Disclosure Schedule Article IV Preamble CVBF Fairness Opinion Section 4.26 CVBF Material Contract Section 4.15 CVBF Options Section 7.1(b) CVBF Permits Section 4.8(a) CVBF Property Section 4.20 CVBF SEC Filings Section 4.9(a) CVBF Shares Section 2.1(a) CVBF Termination Fee Section 11.2(c) Effective Time Section 1.2 Election Section 2.2.1 Election Deadline Section 2.2.2 Election Form Section 2.2.1 Election Form Record Date Section 2.2.1 Exchange Agent Section 2.4(a) Exchange Fund Section 2.5.1 FCBS Preamble FCBS Affiliated Shareholders Recitals FCBS Affiliates Section 6.6 FCBS Articles Section 3.2 FCBS Balance Sheet Section 3.8(c) FCBS Bank Recitals FCBS Board Approval Section 3.5(b) FCBS Board Recommendation Section 5.3(b) FCBS Bylaws Section 3.2 FCBS Confidential Disclosure Schedule Article III Preamble FCBS Employees Section 7.4(a) FCBS Fairness Opinion Section 3.26 FCBS Financial Advisor Section 3.26 FCBS Filings List Section 3.8(a) FCBS Filings Section 3.8(a) FCBS Material Contract Section 3.14 FCBS Option Shares Section 3.3(a) FCBS Options Section 2.5 FCBS Permits Section 3.7 FCBS Property Section 3.20 FCBS Shareholders’ Meeting Section 5.2 FCBS Stock Certificates Section 2.4(b) FCBS Termination Fee Section 11.2(b) Governing Law Section 12.13 Hearing Section 5.2(a) Hearing Notice Section 5.2(a) Holding Company Merger Recitals Indemnified Liabilities Section 7.5(a) Indemnified Persons Section 7.5(a) Indemnifying Party Section 7.5(a) Liens Section 3.4 Mailing Date Section 2.2.1 Multiemployer Plan Section 3.11(b) Option Payment Section 2.6 Option Payments Section 2.6 Permit Application Section 5.2(a) Prohibited Transaction Section 3.11(b) Registration Statement on Form S-4 Section 5.2(b) Regulatory Authority Section 3.8(d) Representatives Section 6.2 Stock Election Section 2.2.1 Stock Proration Factor Section 2.2.3(a)(i...
Defined Terms Section. Action 2.2(e) Affiliate 6.10(a) Agreement Preamble Applicable Procedures 6.10(b) Bank 2.2(b) Burdensome Condition 2.2(d) Closing 1.2(a) Closing Date 1.2(a) Company Preamble Company SEC Reports 2.2(g) Company Subsidiary(ies) 2.2(b) Company’s Knowledge 6.10(f) Contemplated Transactions 2.2(c)(1) DTC 4.2(b) Exchange Act 2.2(d) FDIC 2.2(b) Federal Reserve 2.2(d)
Defined Terms Section. Mono Product 1.33 Other Products 1.33 Outline of Zai Development Plan 3.2(b) Permitted Subcontractors 3.4(c) Prior CDA 6.6 Product Marks 5.7 Royalty Term 4.4(b) SEC 6.5(b) Selling Party 1.33 Sublicense Income for the Same Event 4.5 Sublicense Payment 4.5 Term 7.1 Terminated Jurisdictions 7.3(b) Terminated Products 7.3(b) Territory Infringement 5.3(a) Third Party IP 1.48 Transition Plan 3.3 Zai Development Plan 3.2(b) Zai Indemnitees 9.1
Defined Terms Section. Claims 11.1 Combination Product Dispute 1.55 Commercialization Plan 6.2(a) Competing Program 2.5 Confidentiality Agreement 1.20 CTD 1.17 Development Notice 4.7(b) Development Opt-In Notice 4.7(b) Development Participation Costs Dispute 4.7(b) Development Participation Right 4.7(b) Development Plan 4.2 Dispute 14.1 Effective Date Preamble Enforcing Party 9.4(b) GAAP 1.1 GDP 3.2(a)(vi) GlycoMimetics Preamble GlycoMimetics Indemnitees 11.2 GlycoMimetics Inventions 9.1(d)(i) GlycoMimetics Partner 2.2 IFRS 1.1 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Initial Development Plan 4.2 Joint Clinical Trial Costs Dispute 4.3(b)(iii) Joint Development Committee (JDC) 3.2(a) Joint Inventions 9.1(d)(iii) Licensed ▇▇▇▇ 9.6(a) Losses 11.1 Manufacturing Technology Transfer Agreement 7.2 NDA 1.54 Party Preamble Pharmacovigilance Agreement 5.8 Product Materials 4.7(a) Region 1.7 Remedial Action 5.9 Reversion Background IP 13.6(f) Reversion Collaboration IP 13.6(f) [***] [***] Royalty Term 8.4(b) Rules 14.2(a) SEC 12.3(c) Study 4.3(b)(i) Supply Agreement 7.1 Term 13.1 Third Party Infringement Actions 9.5 Step-In Rights 9.2(d) VAT 8.10(c)
Defined Terms Section. Signing Backlog 2.5(b) Software License Agreement 1.8(b)(ix) Specified IP 9.11 Subcontract Agreement 1.8(b)(vi) Sublease 1.8(b)(viii) Tax Contest 8.4(b)(i) Tax Returns Article X Taxes Article X Taxing Authority 8.4(a) Third Party Article X Trade Compliance Laws Article X Transaction Agreements Article X Transfer Taxes 8.1(c) Transition Services Agreement 1.8(b)(x) U.S. Acquired Assets 1.1 U.S. Assumption Agreement 1.4(a) U.S. Buyer Preamble U.S. Business Employees 9.3(a) U.S. Buyer Plans 9.3(a)(i)(A) U.S. New Buyer Employees 9.3(a)(i)(A) Unaudited Financial Statements 2.5(a) Vendors 2.19 WARN 9.3(h)(iv)
Defined Terms Section. 409A Authorities Section 3.11(e) Adjusted Shareholders’ Equity Section 10.01(f) Agreement Preamble AJCA Section 3.11(e) ALL Section 3.28 Articles of Merger Section 1.02 Bank Section 3.01 Certificate Section 1.06(a) Change in Board Recommendation Section 6.03(b) Claim Section 7.02(a) Closing Section 2.01 Closing Balance Sheet Date Section 6.06 Closing Date Section 2.01 Closing Financial Statements Section 6.06
Defined Terms Section. Competing Program 2.9(a) Compound Invention 11.1(b)(i) Development Budget 4.2 Disputed Matter 16.2 Divest 2.8(c) Excess Funds 4.5(a)
Defined Terms Section. Licensee Preamble Licensee Development Plan 4.3(b) Licensee Indemnitees 13.1 Licensee Territory Data 5.3(a) Licensee Withholding Tax Action 8.8(c) Material Safety Event 11.2(c) Necessary Third Party IP Rights 2.5(a) Non-publishing Party 10.3(e) Party Preamble Parties Preamble [***] [***] Pharmacovigilance Agreement 5.5(c) Product Infringement 9.3(a) Product Marks 7.5 Product Specific Patent 9.2(a) Publishing Party 10.3(e) Receiving Party 10.1(a) Regulatory Milestone Event 8.2(a) Regulatory Milestone Payment 8.2(a) Royalty Term 8.4(d) Sales Milestone Event 8.3(a) Sales Milestone Payment 8.3(a) Segregation Requirements 2.4(b)(i) Sole Inventions 9.1(a) Supply Agreement 6.2 Term 11.1 Third Party IP Notice 2.5(a) Upstream License 2.5(b)
Defined Terms Section. Bankruptcy Code 6.6 Executive Officers 3.4 GCAR 4.4(a) GBM AGILE 4.4(a) IDL 4.5(d) Indemnified Party 10.3 Indemnifying Party 10.3 Joint Steering Committee or JSC 3.1 ▇▇▇▇▇ Indemnitees 10.2 Licensed Trademarks 6.7(a) Prior CDA 7.7 Product Marks 6.7(b) Recipient 7.3 Remedial Action 4.12 Review Period 5.5(f) Royalty Query 5.5(f) Royalty Report 5.5(e) Royalty Term 5.5(b) Securities Regulators 7.6(b) Share Subscription Agreement 5.2 Simcere Indemnitees 10.1 Territory Infringement 6.3
Defined Terms Section. ▇▇▇▇ Trademarks Section 9.6(b) Manufacture Technology Transfer Section 6.2 Manufacturing Technology Transfer Materials Section 6.2 Manufacturing Technology Transfer Plan Section 6.2 Other Product Section 2.8(a) Other Product Transaction Section 2.8(a) Parties Preamble Party Preamble Pharmacovigilance Agreement Section 5.6 Prior CDA Section 10.6 Product Infringement Section 9.3(b) Product Marks Section 9.6(a) Region Section 1.62 Remedial Action Section 5.9 ROFN Section 2.8(a) ROFN Exercise Period Section 2.8(b) ROFN Expiry Date Section 2.8(c) ROFN Negotiation Period Section 2.8(a) Royalty Term Section 8.5(b) [***] [***] [***] [***] SEC Section 10.5(b) Sole Inventions Section 9.1(a)(i) Target Entity Section 1.3 Taxes Section 8.10 Term Section 13.1(a)